Resistant Hypertension: an Approach to Management in Primary Care

Overview

Journal J Family Med Prim Care

Specialty Public Health

Date 2015 May 8

PMID 25949966

Citations 20

Authors

Julian P Yaxley

Sam V Thambar

Affiliations

Soon will be listed here.

Abstract

Hypertension is widely encountered in family medicine. Despite its prevalence, many patients have uncontrolled or difficult-to-control blood pressure. Resistant hypertension is defined as hypertension that is poorly responsive to treatment and requires the use of multiple medications to achieve acceptable blood pressure ranges. It may be a consequence of secondary hypertension or have no identifiable cause. Resistant hypertension is important to recognise because it places patients at risk of end-organ damage. Primary care physicians should be aware of the therapeutic approach for hypertension when traditional therapy fails. This article aims to familiarise readers with the evaluation and management of resistant hypertension by outlining the most recent evidence-based treatment options.

Citing Articles

Approaches and Challenges in Managing Treatment-Resistant Hypertension: A Case Report.

Morano J, Kholoki S Cureus. 2025; 16(12):e75554.

PMID: 39803044 PMC: 11723567. DOI: 10.7759/cureus.75554.

A Retrospective Analysis of the Underlying Health Status of Patients Treated for Stroke in the Emergency Department of a Community Hospital Situated in a Health Professional Shortage Area.

Voura E, Jorgensen T, Stulb J, Mulligan M, Padalino D Cureus. 2024; 16(8):e68150.

PMID: 39347207 PMC: 11438578. DOI: 10.7759/cureus.68150.

Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage.

Singh J, Jackson K, Fang H, Gumanti A, Claridge B, Tang F Cardiovasc Res. 2024; 120(11):1336-1350.

PMID: 38879891 PMC: 11416058. DOI: 10.1093/cvr/cvae103.

Supporting GPs and people with hypertension to maximise medication use to control blood pressure: Protocol for a pilot cluster RCT of the MIAMI intervention.

Morrissey E, Murphy A, Murphy P, OGrady L, Byrne M, Casey M HRB Open Res. 2024; 6:6.

PMID: 38779427 PMC: 11109531. DOI: 10.12688/hrbopenres.13661.2.

A Comprehensive Review on Nanoparticles as Drug Delivery System and Their Role for Management of Hypertension.

Prerna , Bhatt D, Mir K, Kumar V, Rathor S Curr Pharm Biotechnol. 2024; 26(2):169-185.

PMID: 38566387 DOI: 10.2174/0113892010291414240322112508.

References

Black H, Elliott W, Grandits G, Grambsch P, Lucente T, White W . Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003; 289(16):2073-82. DOI: 10.1001/jama.289.16.2073. View

Calhoun D, Jones D, Textor S, Goff D, Murphy T, Toto R . Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51(6):1403-19. DOI: 10.1161/HYPERTENSIONAHA.108.189141. View

Ayala D, Hermida R, Mojon A, Fernandez J . Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int. 2012; 30(1-2):340-52. DOI: 10.3109/07420528.2012.701455. View

Pimenta E, Calhoun D . Treatment of resistant hypertension. J Hypertens. 2010; 28(11):2194-5. DOI: 10.1097/HJH.0b013e32833eafa3. View

Kumar N, Calhoun D, Dudenbostel T . Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control. 2013; 6:139-51. PMC: 3826290. DOI: 10.2147/IBPC.S33984. View

Carter B, Ernst M, Cohen J . Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2003; 43(1):4-9. DOI: 10.1161/01.HYP.0000103632.19915.0E. View

Briganti E, Shaw J, Chadban S, Zimmet P, Welborn T, McNeil J . Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust. 2003; 179(3):135-9. DOI: 10.5694/j.1326-5377.2003.tb05114.x. View

Okamoto L, Gamboa A, Shibao C, Black B, Diedrich A, Raj S . Nocturnal blood pressure dipping in the hypertension of autonomic failure. Hypertension. 2008; 53(2):363-9. PMC: 2665259. DOI: 10.1161/HYPERTENSIONAHA.108.124552. View

Moser M, Setaro J . Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006; 355(4):385-92. DOI: 10.1056/NEJMcp041698. View

10.

Khosla N, Chua D, Elliott W, Bakris G . Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?. J Clin Hypertens (Greenwich). 2005; 7(6):354-6. DOI: 10.1111/j.1524-6175.2005.04451.x. View

11.

Tu K, Chen Z, Lipscombe L . Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ. 2008; 178(11):1429-35. PMC: 2374870. DOI: 10.1503/cmaj.071283. View

12.

Gottlieb T, KATZ F, CHIDSEY 3rd C . Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation. 1972; 45(3):571-82. DOI: 10.1161/01.cir.45.3.571. View

13.

Myat A, Redwood S, Qureshi A, Spertus J, Williams B . Resistant hypertension. BMJ. 2012; 345:e7473. DOI: 10.1136/bmj.e7473. View

14.

Mann J, Schmieder R, McQueen M, Dyal L, Schumacher H, Pogue J . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372(9638):547-53. DOI: 10.1016/S0140-6736(08)61236-2. View

15.

Friedman O, Logan A . Can nocturnal hypertension predict cardiovascular risk?. Integr Blood Press Control. 2011; 2:25-37. PMC: 3172086. DOI: 10.2147/ibpc.s4364. View

16.

Bhatt D, Kandzari D, ONeill W, DAgostino R, Flack J, Katzen B . A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370(15):1393-401. DOI: 10.1056/NEJMoa1402670. View

17.

MADKOUR H, Gadallah M, Riveline B, Plante G, Massry S . Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. Am J Cardiol. 1996; 77(6):23B-25B. DOI: 10.1016/s0002-9149(97)89236-3. View

18.

Esler M, Krum H, Sobotka P, Schlaich M, Schmieder R, Bohm M . Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376(9756):1903-9. DOI: 10.1016/S0140-6736(10)62039-9. View

19.

Setaro J, Black H . Refractory hypertension. N Engl J Med. 1992; 327(8):543-7. DOI: 10.1056/NEJM199208203270808. View

20.

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View